Author

Nicolas Alejandro Fraunhoffer

Centre National de la Recherche ScientifiqueORCID 0000-0003-1561-2563Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Nelson DusettiiD· 2 shared Analía Meilerman Abuelafia· 1 shared Anna Barthelemy· 1 shared Brice ChaneziD· 1 shared Clémentine GaucheriD· 1 shared Daniel GrassoiD· 1 shared Eduardo ChuluyániD· 1 shared Flora PoizatiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Nelson DusettiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 9, 2026

Transcriptomic FOLFIRINOX sensitivity signatures stratify overall survival and reveal directional reclassification after neoadjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic cancer

Clémentine Gaucher, Muge Kaya, Jonathan Garnier…·Brice Chanez

This paper evaluates transcriptomic FOLFIRINOX sensitivity signatures in neoadjuvant pancreatic cancer, finding they predict survival and show directional reclassification after treatment.

DOI 10.64898/2026.09.07.749857

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyTranslational OncologyPeer-reviewedMay 17, 2025

KRAS Inhibition Reverses Chemotherapy Resistance Promoted by Therapy-Induced Senescence-like in Pancreatic Ductal Adenocarcinoma

Analía Meilerman Abuelafia, Patricia Santofimia‐Castaño, Matías Estarás…·Juan Iovanna

This study shows that KRAS inhibition can reverse chemotherapy resistance in PDAC by targeting therapy-induced senescence-like cells, with ERK pathway involvement.

6 citations

humanbulk RNA-seq

𝕏 PostBluesky